Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan.
J Surg Res. 2011 Nov;171(1):226-33. doi: 10.1016/j.jss.2010.01.039. Epub 2010 Feb 23.
Ischemia-reperfusion (I/R) contributes to acute kidney injury (AKI). On the other hand, anti-oxidative drugs help to prevent renal injury caused by I/R. The current study examined whether a new antioxidant, ETS-GS, inhibits reactive oxygen species (ROS) generation and thereby prevents renal I/R injury in rodent models.
Rats with experimentally-induced renal I/R injury were treated concurrently with an intravenous injection of either ETS-GS or saline. Anesthesia was induced with sevoflurane.
Histologic examination revealed marked reduction of interstitial congestion, edema, inflammation, and hemorrhage in kidney tissue harvested 24 h after ETS-GS treatment. Renal I/R-induced secretion of nitric oxide (NO) in serum was inhibited by ETS-GS treatment. Furthermore, malondialdehyde (MDA) levels in the kidney were significantly lower in ETS-GS-treated rats with renal I/R. Moreover, when murine macrophage-like RAW264.7 cells were stimulated with antimycin A in the presence or absence of simultaneous ETS-GS treatment, ETS-GS decreased ROS levels.
Thus, ETS-GS lowered ROS levels in cultured cells, reduced serum NO levels, decreased renal MDA levels, and protected rats against I/R-induced kidney injury. Given these in vitro and in vivo findings, ETS-GS is a strong candidate for future exploration of therapeutic potential in various human I/R diseases.
缺血再灌注(I/R)会导致急性肾损伤(AKI)。另一方面,抗氧化药物有助于预防 I/R 引起的肾损伤。本研究旨在探讨一种新型抗氧化剂 ETS-GS 是否通过抑制活性氧(ROS)的产生,从而预防啮齿动物模型的肾 I/R 损伤。
采用实验性诱导肾 I/R 损伤的大鼠,同时给予 ETS-GS 或生理盐水静脉注射。采用七氟醚诱导麻醉。
组织学检查显示,与生理盐水处理组相比,在 ETS-GS 处理 24 小时后,肾组织中间质充血、水肿、炎症和出血明显减少。ETS-GS 处理抑制了肾 I/R 诱导的血清中一氧化氮(NO)的分泌。此外,肾 I/R 大鼠肾组织中的丙二醛(MDA)水平显著降低。此外,当鼠巨噬样 RAW264.7 细胞在存在或不存在同时 ETS-GS 处理的情况下用抗霉素 A 刺激时,ETS-GS 降低了 ROS 水平。
因此,ETS-GS 降低了培养细胞中的 ROS 水平,降低了血清中 NO 的水平,降低了肾 MDA 水平,并保护了大鼠免受 I/R 诱导的肾损伤。鉴于这些体外和体内发现,ETS-GS 是未来探索各种人类 I/R 疾病治疗潜力的一个有希望的候选药物。